Lifecore Biomedical, Inc. LFCR

Set alert

Price alert · LFCR

All alert types
6.43 USD +0.04 +0.55%

As of Nov 3, 12:47 PM ET

Bid
6.42 × 1
Ask
6.43 × 2
6.41 Day range 6.43
3.63 52-week range 8.98
YTD
-21.45%
1 year
-9.63%
Open
6.41
Prev close
6.39
Mkt cap
243.55M
Vol
95.73K
Avg vol
382.37K
EPS
-1.27
P/E
0.00
Div yield
0.00%
More statistics
Low
6.41
High
6.43
Forward P/E
-9.90
Beta
0.94
Short ratio
11.20
Inst. own
69.84%
Dividend
0.00
Ex-div date
Earnings
Jan 2, 2025
50-d avg
6.51
200-d avg
5.84
1y target
8.00

5m chart

Chart tools
Interval

Chart is warming up

The five-minute interval price history for LFCR has not been loaded yet. Try again in a moment.

Analyst view

Price target (mean) 8.00 +24.5% upside
Target (low)
6.00
Target (mean)
8.00
Target (high)
10.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold2
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 3
  • 1 month ago 3
  • 2 months ago 3

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

LFCR analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.305-0.34 – -0.27-0.0682-347.2%29.75M-1.3%2
Next quarter-0.155-0.16 – -0.150.425-136.5%34.74M-2.7%2
Current year-0.985-1.03 – -0.94-0.322-205.9%128.55M+0.2%2
Next year-0.715-0.83 – -0.60-0.985+27.4%139.35M+8.4%2

Upgrades and downgrades

The latest rating changes

LFCR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 22, 2024Craig-HallumMaintainedBuyBuy
Sep 5, 2024Craig-HallumInitiated—Buy
Aug 28, 2024Barrington ResearchDowngradeOutperformMarket Perform
Sep 1, 2023Barrington ResearchMaintainedOutperformOutperform
Sep 1, 2023Stephens & Co.MaintainedEqual-WeightEqual-Weight
Jun 2, 2023Barrington ResearchMaintainedOutperformOutperform
May 24, 2023Barrington ResearchMaintainedOutperformOutperform
Mar 21, 2023Barrington ResearchMaintained—Outperform
Mar 20, 2023Barrington ResearchMaintained—Outperform
Mar 20, 2023Stephens & Co.DowngradeOverweightEqual-Weight
Mar 17, 2023Stephens & Co.Reiterated—Overweight